International Journal of Enhanced Research in Medicines & Dental Care (IJERMDC),
ISSN: 2349-1590, Vol. 12 Issue 10, October 2025, Impact Factor: 8.325

Periodontal Medicine: A Narrative Review of Systemic Investigations and Surgical-Planning Criteria in Periodontal Patients

Sakshi Verma[1], Janvi Sahu[2], Ritika Arora[3], Deepti Anand[4]

[1,2,3,4]Department of Periodontics and Oral Implantology Post Graduate Institute of Dental Sciences, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India

***Correspondence:-** Dr. Sakshi Verma

ABSTRACT

Periodontal medicine represents the clinical embodiment of the oral–systemic health connection, emphasizing how systemic diseases influence periodontal outcomes and vice versa. With the increasing global burden of comorbidities such as diabetes, cardiovascular disease, renal dysfunction, and anticoagulant use, preoperative systemic evaluation has become a critical step before periodontal surgery. This review synthesizes current evidence from major periodontology and systemic medicine journals to present a comprehensive framework of laboratory investigations essential for periodontal treatment planning in medically compromised patients.

Keywords: periodontitis, systemic disease, diabetes, surgery, investigations, periodontal medicine

INTRODUCTION

Periodontal medicine represents a pivotal intersection between oral and systemic health, highlighting the bidirectional interplay between chronic periodontal inflammation and systemic diseases. Periodontitis induces a state of low-grade systemic inflammation and transient bacteremia, elevating circulating cytokines such as IL-6, TNF-α, and C-reactive protein (CRP). These mediators contribute to endothelial dysfunction, insulin resistance, and atherogenesis, thus linking oral inflammation with systemic disease progression. Systemic investigations before periodontal surgery are essential for identifying underlying medical risks, predicting healing potential, and minimizing complications.

DISCUSSION

Periodontal disease functions as a persistent low-grade inflammatory stimulus capable of influencing several systemic biological pathways.[16–18] The pathogenesis involves complex host–microbe interactions where dysbiotic biofilms provoke exaggerated immune responses, releasing pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). These mediators not only contribute to local tissue destruction but also gain systemic access through the ulcerated pocket epithelium, leading to transient bacteremia. Once in circulation, periodontal pathogens including *Porphyromonas gingivalis*, *Aggregatibacter actinomycetemcomitans*, *Tannerella forsythia*, and *Fusobacterium nucleatum* can initiate endothelial activation, lipid oxidation, and autoimmune mimicry mechanisms, linking oral infection to extraoral inflammatory sequelae.[19,20]

The concept of "periodontal medicine" has therefore emerged to define this bidirectional relationship between periodontal inflammation and systemic diseases such as diabetes mellitus, cardiovascular disease, respiratory disorders, rheumatoid arthritis, and chronic kidney disease. Chronic inflammation originating in the periodontium acts as a systemic amplifier, while systemic diseases may, in turn, exacerbate periodontal destruction by modifying immune, vascular, and metabolic pathways.[21–23] This interdependence necessitates that the periodontist adopt a comprehensive diagnostic perspective, considering not only local tissue health but also systemic biomarkers and medical status before formulating a surgical plan.
Among all systemic comorbidities, **diabetes mellitus** remains the most intensively investigated due to its robust bidirectional association with periodontal disease.[24] Persistent hyperglycemia leads to the formation of advanced glycation

end-products (AGEs) that interact with their receptors (RAGE) on immune and endothelial cells, resulting in exaggerated inflammatory responses and oxidative stress. This state promotes impaired neutrophil chemotaxis, diminished fibroblast function, and delayed angiogenesis—collectively reducing the regenerative potential of periodontal tissues.[25] Furthermore, uncontrolled diabetes elevates levels of IL-6, TNF-α, and C-reactive protein (CRP), perpetuating the inflammatory feedback loop. Periodontal therapy has been shown to modestly improve glycemic control, underscoring the reciprocal influence between metabolic regulation and oral health.[26],[27]

Similarly, **cardiovascular diseases (CVDs)** share overlapping inflammatory mediators with periodontitis. Chronic exposure to bacterial endotoxins such as lipopolysaccharides (LPS) from *P. gingivalis* contributes to endothelial dysfunction and the development of atherosclerotic plaques.[28],[29] Periodontally derived cytokines promote monocyte adhesion to vascular walls, foam cell formation, and plaque instability, linking oral inflammation to myocardial infarction and stroke risk.[30] Patients with a history of CVD require meticulous preoperative evaluation, including blood pressure monitoring, lipid profiling, and medical clearance before periodontal surgery. Adjustments in anesthetic and antibiotic regimens, particularly in patients on antiplatelet or anticoagulant therapy, are also critical for minimizing procedural complications.

Renal dysfunction introduces another dimension of complexity in periodontal management. Reduced renal clearance alters the metabolism of various medications including antibiotics, analgesics, and anesthetics used during surgical procedures.[31] Chronic kidney disease (CKD) is associated with immunosuppression, anemia, and dysregulated bone metabolism, leading to higher susceptibility to infections and delayed wound healing. Periodontal infection, in turn, may aggravate renal impairment by sustaining systemic inflammation and endothelial injury. Therefore, evaluation of serum creatinine, urea levels, and complete blood counts prior to surgery is vital for tailoring treatment plans to the patient's systemic condition.

Systemic coagulopathies and anticoagulant therapy also demand special consideration during periodontal surgery.[32] Patients receiving warfarin or direct oral anticoagulants (DOACs) present an elevated bleeding risk, particularly when invasive flap or graft procedures are planned. Coordination with the physician for adjustment of International Normalized Ratio (INR) within the therapeutic window (ideally ≤3.0) ensures procedural safety without compromising systemic protection. Local hemostatic measures—such as suturing, oxidized cellulose application, and tranexamic acid rinses—further reduce intra- and postoperative bleeding episodes.

Beyond disease-specific implications, emerging research indicates that elevated systemic inflammatory biomarkers such as CRP and dyslipidemia correlate with poorer periodontal healing outcomes.[33],[34] These findings suggest that systemic inflammation and lipid metabolism influence periodontal tissue regeneration and osseointegration, possibly by modulating the local inflammatory milieu and fibroblast response. Hence, assessing CRP levels and lipid profiles may provide predictive insight into surgical prognosis and healing kinetics.

Collectively, the evidence underscores that successful periodontal surgical outcomes depend not merely on technical precision but also on comprehensive systemic health optimization. Incorporating laboratory investigations—such as HbA1c, INR, CBC, serum creatinine, and lipid profile—into preoperative planning ensures safer, individualized treatment. Periodontists, therefore, play a pivotal role within interdisciplinary healthcare teams, bridging dentistry and systemic medicine to achieve holistic patient well-being.

Periodontal disease acts as a chronic inflammatory burden influencing multiple systemic pathways. Pathogenic bacteria like *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans* can translocate into the bloodstream, initiating systemic inflammation and promoting vascular and metabolic dysfunction.

Among systemic conditions, diabetes mellitus remains the most extensively studied in relation to periodontitis. Hyperglycemia enhances oxidative stress and reduces collagen synthesis, leading to delayed wound healing. Similarly, cardiovascular disease, renal impairment, and coagulopathies significantly alter surgical risk and require tailored treatment strategies.

Clinical Implications

Integration of systemic evaluation into periodontal care improves patient safety and treatment predictability. Routine investigations guide clinicians in surgical timing, anesthetic selection, and perioperative management. Diabetic patients with HbA1c <7% show better healing, whereas anticoagulated patients require INR management in collaboration with their physician. Monitoring inflammatory biomarkers such as CRP can also predict regenerative outcomes and systemic stability.

CONCLUSION

Periodontal medicine bridges the gap between oral and systemic health. Proper interpretation of systemic investigations like BT, CT, INR, APTT, HbA1c, CBC, and renal and lipid profiles ensures safe periodontal surgery. Interdisciplinary collaboration and individualized patient management enhance both surgical success and systemic well-being.

REFERENCES

[1]. Offenbacher S. Periodontal diseases: pathogenesis. Ann Periodontol. 1996;1(1):821-878.
[2]. Kornman KS. Mapping the pathogenesis of periodontitis: a new look. J Periodontol. 2008;79(8 Suppl):1560-1568.
[3]. Tonetti MS, Jepsen S, Jin L, Otomo-Corgel J. Impact of the global burden of periodontal diseases. J Clin Periodontol. 2017;44(Suppl 18):S472-S481.
[4]. Preshaw PM, Alba AL, Herrera D, et al. Periodontitis and diabetes: a two-way relationship. Diabetologia. 2012;55(1):21-31.
[5]. Sanz M, Marco Del Castillo A, Jepsen S, et al. Periodontitis and cardiovascular diseases: consensus report. J Clin Periodontol. 2020;47(3):268-288.
[6]. Mealey BL, Ocampo GL. Diabetes mellitus and periodontal disease. Periodontol 2000. 2007;44:127-153.
[7]. Linden GJ, Herzberg MC. Periodontitis and systemic diseases. J Periodontol. 2013;84(4 Suppl):S1-S6.
[8]. Jepsen S, Caton JG, Albandar JM, et al. Periodontal manifestations of systemic diseases. J Clin Periodontol. 2018;45(Suppl 20):S171-S189.
[9]. Kinane DF, Stathopoulou PG, Papapanou PN. Periodontal diseases. Nat Rev Dis Primers. 2017;3:17038.
[10]. Gupta N, Gupta ND, Goyal L, et al. Role of routine laboratory investigations in periodontal surgery. J Indian Soc Periodontol. 2015;19(2):208-212.
[11]. Friberg TR, et al. Management of patients on anticoagulant therapy undergoing oral surgery. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2016;122(3):e141-e149.
[12]. Carranza FA, Newman MG, Takei HH, Klokkevold PR. Carranza's Clinical Periodontology. 13th ed. Elsevier; 2019.
[13]. Lang NP, Bartold PM. Periodontal health. J Clin Periodontol. 2018;45(Suppl 20):S9-S16.
[14]. Graziani F, Karapetsa D, Alonso B, et al. Diabetes mellitus and periodontal diseases: consensus report. Periodontol 2000. 2020;83(1):231-244.
[15]. Slots J. Periodontitis: facts, fallacies and the future. Periodontol 2000. 2017;75(1):7-23.
[16]. Caton JG, Armitage G, Berglundh T, et al. A new classification of periodontal diseases. J Clin Periodontol. 2018;45(Suppl 20):S1-S8.
[17]. Borgnakke WS, Ylöstalo PV, Taylor GW, Genco RJ. Effect of periodontal disease on diabetes: systematic review. J Periodontol. 2013;84(4 Suppl):S106-S112.
[18]. Eke PI, Dye BA, Wei L, et al. Update on prevalence of periodontitis in adults in the United States. J Periodontol. 2015;86(5):611-622.
[19]. Kinane DF, Stathopoulou PG, Papapanou PN. Periodontitis: biology and future directions. Periodontol 2000. 2021;86(1):7-24.
[20]. Slots J. Periodontal infections: bacterial virulence factors. Periodontol 2000. 2010;53(1):66-111.
[21]. Chapple ILC, Genco R. Diabetes and periodontal diseases: a consensus report. J Periodontol. 2013;84(4 Suppl):S106-S112.
[22]. Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis. J Periodontol. 2018;89(Suppl 1):S159-S172.
[23]. D'Aiuto F, Orlandi M, Gunsolley JC. Evidence that periodontal treatment improves biomarkers and CVD outcomes. J Clin Periodontol. 2023;50(1):10-28.
[24]. Sanz M, Ceriello A, Buysschaert M, et al. Scientific evidence on the links between periodontal and general health. J Clin Periodontol. 2013;40(Suppl 14):S106–S112.
[25]. Ide M, Papapanou PN. Epidemiology of association between periodontitis and systemic disease. Periodontol 2000. 2013;62(1):192-217.
[26]. Deschner J, Haak T, Jepsen S, Kocher T. Diabetes mellitus and periodontal disease. Exp Clin Endocrinol Diabetes. 2011;119(9):575-584.
[27]. Sanz M, D'Aiuto F, Deanfield J, Fernandez-Aviles F. European workshop in periodontal health and cardiovascular disease. Eur Heart J Suppl. 2010;12(Suppl B):B13–B22.
[28]. Beck JD, Offenbacher S. Relationships among clinical measures of periodontal disease and their associations with systemic markers. Ann Periodontol. 2002;7(1):79-89.
[29]. Dietrich T, Sharma P, Walter C, Weston P, Beck J. The epidemiological evidence behind the association between periodontitis and incident atherosclerotic CVD. J Clin Periodontol. 2013;40(Suppl 14):S70–S84.

[30]. Lockhart PB, Bolger AF, Papapanou PN, et al. Periodontal disease and atherosclerotic vascular disease. Circulation. 2012;125(20):2520-2544.
[31]. Chambrone L, et al. Periodontal status of patients with chronic kidney disease and renal transplant recipients. J Periodontol. 2013;84(3):385-391.
[32]. Wahl MJ. Dental surgery in anticoagulated patients. Arch Intern Med. 1998;158(15):1610-1616.
[33]. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. J Clin Periodontol. 2008;35(4):277–290.
[34]. Pejcic A, Kesic L, Obradovic R. C-reactive protein as a systemic marker of inflammation in periodontitis. Eur J Clin Microbiol Infect Dis. 2011;30(3):407–414.

Table 1. Key Laboratory Investigations in Periodontal Patients with Systemic Conditions

Investigation	Normal Range	Clinical Significance	Implications for Periodontal Surgery
Bleeding Time (BT)	2–7 minutes	Assesses platelet function and vascular integrity.	Prolonged BT increases surgical bleeding risk; correction advised before procedure.
Clotting Time (CT)	8–15 minutes	Evaluates intrinsic clotting mechanism.	Extended CT suggests coagulopathy; delay surgery until stabilized.
Prothrombin Time (PT/INR)	INR: 0.8–1.2 (normal); ≤3.0 (anticoagulated)	Monitors extrinsic pathway and anticoagulant therapy.	INR >3.0 contraindicates elective surgery; physician coordination required.
Activated Partial Thromboplastin Time (APTT)	25–35 seconds	Assesses intrinsic clotting pathway.	Prolonged APTT signals bleeding tendency; medical clearance essential.
Random Blood Sugar (RBS)	<140 mg/dL	Evaluates current glycemic control.	Postpone surgery if >200 mg/dL; optimize glucose before intervention.
HbA1c	<5.7% (normal); <7% acceptable for surgery	Reflects long-term glycemic control over 3 months.	HbA1c >7% linked to impaired healing and infection risk.
Complete Blood Count (CBC)	WBC: 4,000–10,000/μL	Assesses anemia, infection, and immune status.	Leukocytosis or anemia may impair wound healing; correct before surgery.
Serum Creatinine	0.6–1.2 mg/dL	Indicates renal function and drug clearance.	Adjust anesthetic or antibiotic dosing if abnormal.
Lipid Profile	LDL <130 mg/dL, HDL >40 mg/dL	Correlates with cardiovascular risk.	Uncontrolled dyslipidemia may affect regenerative outcomes.
C-Reactive Protein (CRP)	<1 mg/L	Marker of systemic inflammation.	Elevated CRP suggests infection; postpone elective surgery.